Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

25-plus years of Big Pharma megadeals

By Brian Buntz | June 9, 2024

M&A Merger and acquisition business finance concept. Businessman pressing button.

[Adobe Stock]

In February, Novo Holdings announced one of the largest M&A deals in recent memory with its plans to acquire Catalent, a leading contract drug manufacturer, for a cool $16.5 billion. The deal could accelerate production of Novo Nordisk’s blockbuster diabetes and weight-loss medications, Ozempic and Wegovy, given skyrocketing demand.

But while the Novo-Catalent deal marks one of the largest recent acquisitions, Big Pharma megadeals, in fact, have shrunk over the decades. Consider Pfizer’s 1999 acquisition of Warner-Lambert for $90.2 billion, which equates to $146 billion today when adjusted for inflation. 1999 also saw the $67 billion union of Astra and Zeneca, which equates to $111.4 billion today. 

It is true, however, that the 2010s did see a trio of big deals, two involving Allergan. This includes Actavis’ acquisition of Allergan in 2015 for $80.6 billion, Takeda’s purchase of Shire plc in 2018 for $69.4 billion and Abbvie’s acquisition of Allergan in 2019 for $66.8 billion — all inflation-adjusted.

See how the deals stack up below — the table further down has year information:

For context, note that in Q1 2024, the cumulative value for M&A deals was $43.5 billion, according to GlobalData. Yet deals worth at least $1 billion are up some 71% compared to the same quarter in 2023.

Trends contributing to the relative resurgence are worries about the Inflation Reduction Act. Big Pharma is increasingly favoring smaller, more targeted acquisitions.

Oncology propelling a significant share of M&A

GlobalData notes that oncology was the top therapy area for M&A deals in Q1 2024, with a total deal value of $29 billion. In addition, companies developing antibody-drug conjugates (ADCs) and radiopharmaceuticals attracted high M&A investment, with notable acquisitions such as Johnson & Johnson’s $2 billion purchase of Ambrx Biopharma and AstraZeneca’s $2 billion acquisition of Fusion Pharmaceuticals.

This fierce competition for cancer therapies is nothing new. Bristol-Myers Squibb shelled out $74 billion for Celgene in 2019, largely to capture its powerhouse oncology portfolio, including the blockbuster drug Revlimid. Pfizer followed suit in 2023, dropping $43 billion on Seagen to bolster its ADC arsenal. And the list goes on: AbbVie’s $21 billion move for Pharmacyclics secured Imbruvica for blood cancers, while Gilead Sciences snagged Trodelvy, a promising ADC for triple-negative breast cancer, through its acquisition of Immunomedics for $21 billion.

Rounding up the biggest deals in recent memory

But which deals have made the biggest mark on the industry in recent decades? The table below ranks the biggest mergers of the past 25+ years, revealing the players and the price tags that redefined the pharmaceutical landscape.

Target Year Value ($ billions) Inflation Adjusted Value ($ billions)
Pfizer Warner-Lambert 1999 90 146.4
Zeneca Astra AB 1998 67 111.4
Bristol-Myers Squibb Celgene 2019 74 90.65
Actavis Allergan, Inc 2015 70.5 80.6
Takeda Pharmaceutical Shire plc 2018 64.3 69.4
Abbvie Allergan plc 2019 63 66.8
Pfizer Seagen 2023 43 44.25
Hoechst AG Rhône-Poulenc 1998 43 71.5
Teva Pharmaceutical Industries Actavis Generics 2016 40.5 53.23
Johnson & Johnson Actelion 2017 30 38.37
Amgen Horizon Therapeutics 2023 27.8 28.59
Ciba-Geigy Sandoz 1996 27 46.6
Monsanto Pharmacia & Upjohn 1999 26.5 43.1
Actavis Forest Laboratories 2014 25 33.1
Abbvie Pharmacyclics 2015 21 28.39
Gilead Sciences Immunomedics 2020 21 25.43
Sanofi Genzyme 2011 20.1 28.45

Filed Under: Drug Discovery and Development, RD
Tagged With: antibody-drug conjugates, blockbuster oncology deals, industry consolidation, oncology drug development, pharmaceutical mergers and acquisitions, R&D pipeline, targeted cancer therapies
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].

Related Articles Read More >

Unlocking PROTAC potential through better delivery
2026 PharmSci 360 adds tracks on research credibility and post-animal drug development
A pharmaceutical technician performs aseptic compounding inside a sterile biosafety cabinet, preparing a cell culture for biologic drug development under strict quality control conditions.
FDA logs more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide
The division of the staff into two divisions of the company. Mass layoffs, work optimization and cost reduction. Crisis and downsizing of business. Reduce and save business. Keep the best employees.
As 59% fewer pharma companies cut staff in Q2 in 2026, job postings rise 15%
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE